Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

SkartaNYAB Plc: Share issue directed to Power Forze AB's shareholders has been executed and trading in new shares begins

SkartaNYAB PlcCOMPANY ANNOUNCEMENT05 September 2022 at 09:30SkartaNYAB Plc: Share issue directed to Power Forze AB’s shareholders has been executed and trading in new shares begins SkartaNYAB Plc announced on 26 August 2022 that it arranges a directed share issue for Power Forze AB’s shareholders as a part of the transaction regarding the acquisition of all shares in Power Forze AB. Acquisition and decisions regarding the related share issue have been executed, and new shares have been registered in the Finnish Trade Register. Trading in new shares begins at Nasdaq First North Growth

BioStock: Stayble reaches important milestone – patient recruitment completed

Stayble Therapeutics recently recruited the last patient to the company’s phase IIb study with the drug candidate STA363 for discogenic chronic low back pain. The fact that the study is now fully recruited is in line with the communicated timetable to present study results by the end of 2023. The company’s CEO Andreas Gerward and CSO Anders Lehmann comments on the important milestone.Read the full article at biostock.se: https://www.biostock.se/en/2022/09/stayble-reaches-important-milestone-patient-recruitment-completed/ This is a press release from BioStock - Connecting Innovation &

Forxiga approved in China for CKD

5 September 2022 07:05 BST Forxiga approved in China for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes Approval marks the first SGLT2 inhibitor approved in China for chronic kidney disease in adult patients with and without type-2 diabetes AstraZeneca's Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in China to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death and hospitalisation for

Inhalation Sciences receives new order worth 360,000 SEK from long-term global pharma client

(Stockholm, 5 September 2022) Inhalation Sciences AB (ISAB) has received a purchase order worth 360,000 SEK for development and required software update work from a long-term client, a leading global pharmaceutical company.The client has an extensive generics pipeline and robust R&D organisation. It has ISAB’s high-precision aerosol generation system PreciseInhale® installed in-house, as well as its in vitro lung simulation module DissolvIt®. Prior to purchase and installation, the client carried out a series of successful clinical research projects with Inhalation Research Services - ISAB’

ASSA ABLOY acquires Control iD in Brazil

ASSA ABLOY has signed an agreement to acquire Control iD, a leading developer of hardware and software solutions for access control and time & attendance in Brazil. “I look forward to welcoming Control iD and their employees into the ASSA ABLOY Group. Control iD is a strategic technological addition; reinforcing our current access control and biometrics offerings, providing complementary growth opportunities, and enabling us to grow our market leadership in emerging markets,” says Nico Delvaux, President and CEO of ASSA ABLOY. "Control iD’s focus on innovative biometric technologies,

Imfinzi approved in US for biliary tract cancer

5 September 2022 07:00 BST Imfinzi plus chemotherapy approved in the US as the first immunotherapy regimen for patients with advanced biliary tract cancer Approval based on TOPAZ-1 Phase III trial results, which showed Imfinzi combination reduced risk of death by 20% vs. chemotherapy alone AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin). The approval by the Food and Drug Administration (FDA) was based on

Mycronic presents new financial and sustainability targets

Mycronic AB (publ) presents new financial targets for the period until 2027-2030. The sustainability target is presented alongside the financial targets.   Mycronic’s new financial and sustainability targets for the period until 2027-2030 are the following:   · Mycronic will reach net sales of SEK 10 billion. · EBIT will exceed SEK 2 billion. · Mycronic will reduce own CO2 emissions by 50 percent.   The new targets will be presented today at Mycronic’s Capital Markets Day at the company’s head office in Täby. The Capital Markets Day will be streamed live and can be

Loudspring carries out a directed share issue of EUR 1.5 million

Loudspring OyjCompany release, inside information5 September 2022, 9:00 (EET) Based on the authorization granted by the Annual General Meeting of the Company on 20 June 2022, the Board of Directors of Loudspring Oyj (“Loudspring” or the “Company”) have on 4 September 2022 resolved on a directed share issue of EUR 1.5 million to a group of private investors (the “Share Issue”). In the Share Issue, 22 461 540 new class A shares (the “Offer Shares”) were offered. The subscription price in the Share Issue was set at EUR 0,065 per Offer Share and amounts to a total of EUR 1.5 million.

DanCann Pharma A/S: Notice of extraordinary general meeting

The Board of Directors hereby convenes an extraordinary general meeting of DanCann Pharma A/S, CVR-no. 39 42 60 05 (the “Company”), to be held on Tuesday, 20 September 2022 at 10:00 am (CET) at the registered office of the Company, Rugvænget 5, DK-6823 Ansager The agenda for the extraordinary general meeting is as follows: 1. Proposed resolution to authorise the Board of Directors to increase the share capital with pre-emption rights for the Company’s shareholders. 2. Proposed resolution to authorise the Board of Directors to increase the share capital without pre-emption

Pharmacolog i Uppsala AB (publ) intends to carry out a new issue of units of 19.2 MSEK

EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA, ELLER I NÅGON ANNAN JURISDIKTION DÄR DISTRIBUTION AV DETTA PRESSMEDDELANDE SKULLE VARA OLAGLIG ELLER KRÄVA YTTERLIGARE ÅTGÄRDER ÄN SÅDANA ÅTGÄRDER SOM FÖLJER AV SVENSK RÄTT. Styrelsen för Pharmacolog i Uppsala AB (publ) (”Pharmacolog” eller ”Bolaget”) har idag, med bemyndigande från bolagsstämman den 24 maj 2022, beslutat om en företrädesemission av units bestående av aktier av serie B

Metsä Group to recruit 65 new specialists through apprenticeship training

Metsä Group press release 5 September 2022Metsä Group is inviting applications for its apprenticeship training programme, which will begin in January 2023. Approximately 65 new jobs will be offered in our production units across Finland.  Metsä Group’s 18-month apprenticeship training programme has become a well-established way for the company to secure its future labour needs and promote competence development.  In the apprenticeship training programme starting in January 2023, successful applicants can complete a further vocational qualification, specialising in the wood product or

Skanska builds highway section in eastern Czech Republic for EUR 47M, about SEK 490M

Skanska has signed a contract with National Highway Authority of the Czech Republic to build a highway in Moravský Písek, in eastern Czech Republic. The contract is worth EUR 47M, about SEK 490M, which will be included in the order bookings for Europe for the third quarter 2022.The construction of the 4.1-kilometer section between Moravský Písek and Bzenec, including four bridges and one multi-level crossing, will be financed by the European Regional Development Fund, OP Integrated Infrastructure 2014-2020 and the state budget. The expected construction commencement date is September

Vinted UAB announces final outcome in the offer to the shareholders of Rebelle AB (publ)

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or the United States or in any other jurisdiction where such offer would be prohibited by applicable law pursuant to legislation, restrictions and regulations in the relevant jurisdiction. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled "Important

Combing light with sharper teeth

Microcombs have widely differing application areas – they can help us discover planets outside our solar system as well as track diseases in our bodies. New research results at Chalmers University of Technology, Sweden, now gives a deeper understanding of how the line width in the combs works, something that will, among other things, enable even more precise measurements in the future. And the discovery was made almost by coincidence. A ruler made of light. That is the simplified comparison that is commonly used to describe what a microcomb is. In short, the principle is based

Herantis Pharma Plc's shares subscribed with option rights

Herantis Pharma Plc, Company release, September 5, 2022 at 8:00 a.m. EEST An aggregate number of 2,400 new shares of Herantis Pharma Plc ("Herantis") have been subscribed for with option rights under the option program 2010. The new shares have been registered with the trade register maintained by the Finnish Patent and Registration Office today. The new shares will confer shareholder rights in Herantis after they have been issued in the book-entry system, on or about 2 September 2022. Trading with the new shares is expected to commence on the Nasdaq First North Growth Market Finland

Management's purchase of shares

Company announcement no. 78 Copenhagen, September 5, 2022 The company's CEO, CTO from “Shape Robotics Denmark” and the Content Director and Business Development Director from “Shape Robotics Romania” has chosen to invest an additional +140.000 DKK total in the company’s share. Furthermore, the Content Director and the Business Development Director (Romania) have officially offered to the Board of Directors (subject to approval) to convert part of the yearly earnings to shares in the company. “The growth potential of this company for the next years is immense, and I look forward

Transaction with shares in Curasight A/S made by managerial employee

COPENHAGEN – Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS).   The Company’s managerial employee have given Curasight power of attorney on her behalf to publish purchase of Curasight shares as managerial employee conducted the 1 September 2022.The transaction comprises the following managerial employee; Name Position Aggregated volume Price, DKK Hanne Damgaard Jensen Chief Development Officer 7.600 97.964Total 7,600 97.964 Hanne Damgaard Jensen

Stena Estelle - the newest and largest ship in Stena Line's fleet in the Baltic Sea - is now officially named!

On 3 September 2022, a ceremony was held to name the new vessel on the Gdynia-Karlskrona line. Champagne was broken on the side of the Stena Estelle ferry by the Deputy Mayor of Gdynia for Economy, Katarzyna Gruszecka-Spychała, the ship's godmother.“Sail on the Baltic Sea, connecting Gdynia with Karlskrona, Poland with Sweden. Be a joy for the crew and passengers on every voyage. Bring glory to those who built you! I name you Stena Estelle”, said Katarzyna Gruszecka-Spychala, and then, as tradition demands, she broke the champagne on the side of the ship. The ceremony was attended by

First subject vaccinated in COVID-19 Phase III clinical trial for ABNCoV2 as a booster vaccine

Hørsholm, Denmark, September 2, 2022 – ExpreS[2]ion Biotech Holding AB’s affiliate ExpreS[2]ion Biotechnologies ApS (“ExpreS[2]ion") announces that a Phase III clinical trial to evaluate the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine has been initiated by Bavarian Nordic, including the vaccination of the first subject. The trial aims to demonstrate non-inferiority of ABNCoV2 as a booster vaccine for individuals with previous COVID-19 disease or vaccination compared to the licensed mRNA vaccine Comirnaty®. Initial trial results are expected towards the end of 2022.The

Nordea Bank Abp: Repurchase of own shares on 02.09.2022

Nordea Bank AbpStock exchange release – Changes in company’s own shares02.09.2022 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 02.09.2022 completed repurchases of own shares (ISIN: FI4000297767) as follows: Trading Number of Weighted average Total cost, EUR* **venue (MIC shares price / share, EUR* Code) **XHEL 350,000 9.16 3,207,190.00CEUX 370,000 9.17 3,392,980.98TQEX 47,000 9.17 431,017.25XSTO 400,000 9.18 3,

Remedy Entertainment Oyj: Managers' Transactions – Henri Österlund

REMEDY ENTERTAINMENT OYJ – Managers' Transactions 2 September 2022 7.00 p.m. (EEST)____________________________________________Person subject to the notification requirementName: Accendo Capital SICAV RAIFPosition: Closely associated person(X) Legal person(1):Person Discharging Managerial Responsibilities In IssuerName: Henri ÖsterlundPosition: Member of the BoardIssuer: REMEDY ENTERTAINMENT OYJLEI: 7437003VZ3JPF7DBTG92Notification type: INITIAL NOTIFICATIONReference number: 19143/4/4____________________________________________Transaction date: 2022-08-31Venue:

Remedy Entertainment Oyj: Managers' Transactions – Henri Österlund

REMEDY ENTERTAINMENT OYJ – Managers' Transactions 2 September 2022 7.00 p.m. (EEST)____________________________________________Person subject to the notification requirementName: Accendo Capital SICAV RAIFPosition: Closely associated person(X) Legal person(1):Person Discharging Managerial Responsibilities In IssuerName: Henri ÖsterlundPosition: Member of the BoardIssuer: REMEDY ENTERTAINMENT OYJLEI: 7437003VZ3JPF7DBTG92Notification type: INITIAL NOTIFICATIONReference number: 19144/4/4____________________________________________Transaction date: 2022-09-01Venue:

Staffordshire University team make shortlist at higher education Oscars

Staffordshire University’s Library and Learning Services team has been shortlisted for an award at the higher education equivalent of the Oscars.The ‘Outstanding Library Team’ is one of 20 categories at the THE Awards which is taking place on 17 November in central London. The University entry focuses on the full library service redesign completed in March 2021 during which ‘digital on demand’ was adopted as a principal to improve the way library and customer service is organised and delivered. This involved positioning the University’s digital assistant app Beacon as the first port of

There are no items matching the current filter
There are no more items matching the current filter
Back to top